A population‐based multistate model for diffuse large B‐cell lymphoma–specific mortality in older patients-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A population‐based multistate model for diffuse large B‐cell lymphoma–specific mortality in older patients

Published:2019-02 Issue:11 Volume:125 Page:1837-1847
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Çağlayan Çağlar¹^ORCID,Goldstein Jordan S.²,Ayer Turgay¹,Rai Ashish³,Flowers Christopher R.²^ORCID

Affiliation:

1. H. Milton Stewart School of Industrial and Systems Engineering, Georgia Institute of Technology Atlanta Georgia

2. Winship Cancer Institute of Emory University Atlanta Georgia

3. Outcomes Research, Surveillance and Health Services Research Program, American Cancer Society Inc Atlanta Georgia

Funder

National Cancer Institute

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.31981

Reference56 articles.

1. 2016 US lymphoid malignancy statistics by World Health Organization subtypes

2. Improving Outcomes for Patients With Diffuse Large B-Cell Lymphoma

3. CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma

4. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

5. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Higher Mortality in Patients With Diffuse Large B-cell Lymphoma Pre-Existing Arterial Hypertension—Real World Data of the Polish Lymphoma Research Group;Heart, Lung and Circulation;2024-05

2. Charlson Comorbidity Index (CCI) in Diffuse Large B-cell Lymphoma: A New Approach in a Multicenter Study;Indian Journal of Hematology and Blood Transfusion;2022-09-28

3. Correction to: Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial;PharmacoEconomics - Open;2022-09-12

4. Approximation of Long-Term Survival with Polatuzumab Vedotin Plus Bendamustine and Rituximab for Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: Results Based on The GO29365 Trial;PharmacoEconomics - Open;2022-07-28

5. Ofatumumab with iphosphamide, etoposide and cytarabine for patients with transplantation‐ineligible relapsed and refractory diffuse large B‐cell lymphoma;British Journal of Haematology;2022-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3